Higher mortality in lung cancer patients with COVID-19? A systematic review and meta-analysis

Lei, Haike; Yang, Yue; Zhou, Wei; Meng-yang, Zhang; Shen, Yang; Tao, Dan; Wang, Lulu; Lei, Qinghua; Wang, Ying; Wu, Yongzhong

doi:10.1016/j.lungcan.2021.05.002

Cited by 31 publications

(18 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several systematic reviews and meta-analysis have been published since 2020. They identified several independent risk factors for COVID-19 death, including increasing age [ 2 - 11 ], male sex [ 5 , 7 - 15 ], hypertension [ 10 , 11 , 13 , 14 , 16 - 18 ], diabetes mellitus [ 8 , 10 , 11 , 13 - 19 ], obesity [ 2 , 6 , 11 ], cardiovascular disease (CVD) [ 10 , 11 , 14 , 16 - 18 , 20 ], cerebrovascular disease [ 11 , 14 , 20 ], chronic kidney disease [ 10 , 11 , 14 , 17 , 20 ], chronic obstructive pulmonary disease (COPD) [ 5 , 8 , 10 - 12 , 16 - 18 , 20 ], cancer [ 6 , 8 , 11 , 17 , 18 , 20 - 22 ], dementia [ 3 ], frailty [ 23 , 24 ], pneumonia [ 13 ], and end-organ damage [ 13 ]. Among these risk factors, the most consistently identified predictors were aging, male sex, hypertension, diabetes, CVD, COPD, and cancer.…”

Section: Introductionmentioning

confidence: 99%

Barthel’s Index: A Better Predictor for COVID-19 Mortality Than Comorbidities

et al. 2022

View full text Add to dashboard Cite

BackgroundThe most consistent identified mortality determinants for the new coronavirus 2019 infection are aging, male sex, cardiovascular/respiratory diseases, and cancer. They were determined from heterogeneous cohorts that included patients with different disease severity and previous condition.The main goal of our study was to test if activities of daily living (ADL) dependence measured by Barthel's index could be a predictor for COVID-19 mortality. MethodsProspective cohort study with a consecutive sample of 340 COVID-19 patients representing patients from all over the Northern region of Portugal from 10/2020 to 03/2021. Mortality risk factors were determined controlling for demographics, activities of daily living (ADL) dependence, admission time, comorbidities, clinical manifestations, and delay-time for diagnosis. Central tendency measures were used to analyze continuous variables and absolute numbers (proportions) for categorical variables. For univariable analysis we used T-Test/Chi-Square/Fisher Exact Test as appropriate (α=0.05). Multivariable analysis was performed using logistic regression. Statistical software: IBM®SPSS®27. ResultsThe cohort included 340 patients (55.3% females, mean age 80.6±11.0) with a mortality rate of 19.7%. Aging, ADL dependence, pneumonia and dementia were associated with mortality and dyslipidemia and obesity with survival in univariate analysis. In multivariable analysis dyslipidemia (OR=0.35, 95%CI:0.17-0.71) was independently associated with survival. Age ≥ 86-year-old (pooled OR 2.239, 95% CI:1.100-4.559), pneumonia (pooled OR 3.00, 95% CI: 1.362-6.606), and ADL dependence (pooled OR 6.296, 95% CI: 1.795-22.088) were significantly related to mortality (ROC AUC=82.1% (p<0.0001)). ConclusionADL dependence, aging and pneumonia are the 3 main COVID-19 mortality predictors among an elderly population.

show abstract

Section: Introductionmentioning

confidence: 99%

Barthel’s Index: A Better Predictor for COVID-19 Mortality Than Comorbidities

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In a recent meta-analysis of 52 studies and 18,650 cancer patients with COVID-19, the mortality rate was 25.6% [ 4 ]. Patients with hematological and lung malignancies, as well as those with active and/or advanced disease, have a persistently increased risk [ 5 , 6 , 7 ]. In Greece, vaccination of vulnerable groups such as elderly citizens and cancer patients of all ages was prioritized in mid-March 2021.…”

Section: Introductionmentioning

confidence: 99%

Responses to SARS-CoV-2 Vaccination in Patients with Cancer (ReCOVer Study): A Prospective Cohort Study of the Hellenic Cooperative Oncology Group

Linardou

Spanakis

Koliou

et al. 2021

Cancers

View full text Add to dashboard Cite

Data on the effectiveness and safety of approved SARS-CoV-2 vaccines in cancer patients are limited. This observational, prospective cohort study investigated the humoral immune response to SARS-CoV-2 vaccination in 232 cancer patients from 12 HeCOG-affiliated oncology departments compared to 100 healthcare volunteers without known active cancer. The seropositivity rate was measured 2–4 weeks after two vaccine doses, by evaluating neutralising antibodies against the SARS-CoV-2 spike protein using a commercially available immunoassay. Seropositivity was defined as ≥33.8 Binding-Antibody-Units (BAU)/mL. A total of 189 patients and 99 controls were eligible for this analysis. Among patients, 171 (90.5%) were seropositive after two vaccine doses, compared to 98% of controls (p = 0.015). Most seronegative patients were males (66.7%), >70-years-old (55.5%), with comorbidities (61.1%), and on active treatment (88.9%). The median antibody titers among patients were significantly lower than those of the controls (523 vs. 2050 BAU/mL; p < 0.001). The rate of protective titers was 54.5% in patients vs. 97% in controls (p < 0.001). Seropositivity rates and IgG titers in controls did not differ for any studied factor. In cancer patients, higher antibody titers were observed in never-smokers (p = 0.006), women (p = 0.022), <50-year-olds (p = 0.004), PS 0 (p = 0.029), and in breast or ovarian vs. other cancers. Adverse events were comparable to registration trials. In this cohort study, although the seropositivity rate after two vaccine doses in cancer patients seemed satisfactory, their antibody titers were significantly lower than in controls. Monitoring of responses and further elucidation of the clinical factors that affect immunity could guide adaptations of vaccine strategies for vulnerable subgroups.

show abstract

“…A meta-analysis of patients with lung cancer and COVID-19, which included 13 studies, showed that the pooled mortality of patients with lung cancer and COVID-19 (up to 25–42%) was significantly higher than the mortality of patients with other cancers ( 9 , 10 ). This may be due to different pathophysiological factors, such as pulmonary compromise and smoking history, in patients with lung cancer, compared with other cancers ( 11 ).…”

Section: Introductionmentioning

confidence: 99%

Network Pharmacology and Comparative Transcriptome Reveals Biotargets and Mechanisms of Curcumol Treating Lung Adenocarcinoma Patients With COVID-19

Xiong²,

et al. 2022

Front. Nutr.

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) pandemic has led to 4,255,892 deaths worldwide. Although COVID-19 vaccines are available, mutant forms of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have reduced the effectiveness of vaccines. Patients with cancer are more vulnerable to COVID-19 than patients without cancer. Identification of new drugs to treat COVID-19 could reduce mortality rate, and traditional Chinese Medicine(TCM) has shown potential in COVID-19 treatment. In this study, we focused on lung adenocarcinoma (LUAD) patients with COVID-19. We aimed to investigate the use of curcumol, a TCM, to treat LUAD patients with COVID-19, using network pharmacology and systematic bioinformatics analysis. The results showed that LUAD and patients with COVID-19 share a cluster of common deregulated targets. The network pharmacology analysis identified seven core targets (namely, AURKA, CDK1, CCNB1, CCNB2, CCNE1, CCNE2, and TTK) of curcumol in patients with COVID-19 and LUAD. Clinicopathological analysis of these targets demonstrated that the expression of these targets is associated with poor patient survival rates. The bioinformatics analysis further highlighted the involvement of this target cluster in DNA damage response, chromosome stability, and pathogenesis of LUAD. More importantly, these targets influence cell-signaling associated with the Warburg effect, which supports SARS-CoV-2 replication and inflammatory response. Comparative transcriptomic analysis on in vitro LUAD cell further validated the effect of curcumol for treating LUAD through the control of cell cycle and DNA damage response. This study supports the earlier findings that curcumol is a potential treatment for patients with LUAD and COVID-19.

show abstract

Higher mortality in lung cancer patients with COVID-19? A systematic review and meta-analysis

Cited by 31 publications

References 19 publications

Barthel’s Index: A Better Predictor for COVID-19 Mortality Than Comorbidities

Barthel’s Index: A Better Predictor for COVID-19 Mortality Than Comorbidities

Responses to SARS-CoV-2 Vaccination in Patients with Cancer (ReCOVer Study): A Prospective Cohort Study of the Hellenic Cooperative Oncology Group

Network Pharmacology and Comparative Transcriptome Reveals Biotargets and Mechanisms of Curcumol Treating Lung Adenocarcinoma Patients With COVID-19

Contact Info

Product

Resources

About